EMV Capital (LSE:EMVC) reported net assets of £33.4 million in its interim results, with net asset value per share increasing 145% to £1.20.
The increase was largely attributable to the deconsolidation of diagnostics companies Glycotest and ProAxsis. On an underlying basis, EMV Capital reported a 16% increase in Adjusted NAV per share.
Assets under management stood at £117.5 million as of 30 June 2026.
One-Off Gain Results in £17.8 Million Headline Profit
EMV Capital reported a headline profit of £17.8 million for the period, reflecting a one-off non-cash gain associated with changes in the treatment of portfolio companies.
The group’s core business recorded an underlying loss during the period as EMV Capital continued investing in its infrastructure and portfolio.
The company has been developing AI-enabled infrastructure, expanding recurring-revenue services and syndicating third-party capital as part of its investment platform.
Portfolio Companies Progress Development Programmes
EMV Capital reported developments across several companies in its portfolio during the period.
AMR Bio continued work on its antimicrobial programme ahead of a planned Phase 3 programme, while DeepTech Recycling progressed its plastic-to-oil technology.
SageTech continued development of its anaesthetic gas capture systems, and Sofant advanced its phased-array antenna technology.
Glycotest and ProAxsis, meanwhile, secured additional funding following their deconsolidation and are now operating on independent development paths.
EMV Capital Focuses on Deep Tech, Life Sciences and Sustainability
EMV Capital is a venture capital investment group focused on deep technology, life sciences and sustainability.
The group operates through corporate finance, value creation services and fund management, with portfolio exposure to areas including diagnostics, antimicrobial therapies, advanced recycling, medical gas technologies and communications hardware.
Leave a Reply